Yan Fan, Zhen Tian, Hongyan Zheng, Rongman Xu, Boyu Li, Shanshan Wang, Zhenli Huang, Meijia Wang, Dan Ding, Jianping Zhao, Jungang Xie
{"title":"Six1通过调节Tp53促进肺纤维化肺泡上皮衰老","authors":"Yan Fan, Zhen Tian, Hongyan Zheng, Rongman Xu, Boyu Li, Shanshan Wang, Zhenli Huang, Meijia Wang, Dan Ding, Jianping Zhao, Jungang Xie","doi":"10.1016/j.intimp.2025.115554","DOIUrl":null,"url":null,"abstract":"<div><div>Idiopathic pulmonary fibrosis (IPF) is a deadly respiratory condition distinguished by gradual fibrotic restructuring and diminishing pulmonary capacity, with cellular senescence serving as a critical factor in its pathogenesis. This study investigated the function of Sine oculis homeobox homologue 1 (Six1), a transcription factor, in pulmonary fibrosis (PF) and assessed its therapeutic potential as a target. The expression of Six1 was reduced in type II alveolar epithelial cells (AECII) in both patients with IPF and mouse models of PF induced by bleomycin (BLM). Conditional overexpression of Six1 in AECII exacerbated fibrosis severity, as confirmed by histological analysis and impaired lung function. RNA sequencing indicated the involvement of Six1 in pathways related to immune response, inflammation, and cellular senescence. Mechanistic studies revealed that Six1 promotes cellular senescence in AECII by directly upregulating Tp53 transcription, a process mitigated by treatment with PFN-α, a Tp53 inhibitor. Inhibition of Six1 using the specific repressor NCGC00378430 (NCG) attenuated fibrotic changes and improved pulmonary function in both Six1-overexpressing and wild-type mice. These findings suggest that Six1 is a contributor to the progression of IPF by regulating AECII senescence, emphasizing the therapeutic potential of targeting Six1 to alleviate PF. This study underscores the necessity of exploring Six1 inhibitors further as promising candidates for treating IPF.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"166 ","pages":"Article 115554"},"PeriodicalIF":4.7000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Six1 promotes alveolar epithelium senescence in pulmonary fibrosis through regulating Tp53\",\"authors\":\"Yan Fan, Zhen Tian, Hongyan Zheng, Rongman Xu, Boyu Li, Shanshan Wang, Zhenli Huang, Meijia Wang, Dan Ding, Jianping Zhao, Jungang Xie\",\"doi\":\"10.1016/j.intimp.2025.115554\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Idiopathic pulmonary fibrosis (IPF) is a deadly respiratory condition distinguished by gradual fibrotic restructuring and diminishing pulmonary capacity, with cellular senescence serving as a critical factor in its pathogenesis. This study investigated the function of Sine oculis homeobox homologue 1 (Six1), a transcription factor, in pulmonary fibrosis (PF) and assessed its therapeutic potential as a target. The expression of Six1 was reduced in type II alveolar epithelial cells (AECII) in both patients with IPF and mouse models of PF induced by bleomycin (BLM). Conditional overexpression of Six1 in AECII exacerbated fibrosis severity, as confirmed by histological analysis and impaired lung function. RNA sequencing indicated the involvement of Six1 in pathways related to immune response, inflammation, and cellular senescence. Mechanistic studies revealed that Six1 promotes cellular senescence in AECII by directly upregulating Tp53 transcription, a process mitigated by treatment with PFN-α, a Tp53 inhibitor. Inhibition of Six1 using the specific repressor NCGC00378430 (NCG) attenuated fibrotic changes and improved pulmonary function in both Six1-overexpressing and wild-type mice. These findings suggest that Six1 is a contributor to the progression of IPF by regulating AECII senescence, emphasizing the therapeutic potential of targeting Six1 to alleviate PF. This study underscores the necessity of exploring Six1 inhibitors further as promising candidates for treating IPF.</div></div>\",\"PeriodicalId\":13859,\"journal\":{\"name\":\"International immunopharmacology\",\"volume\":\"166 \",\"pages\":\"Article 115554\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International immunopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1567576925015450\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925015450","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Six1 promotes alveolar epithelium senescence in pulmonary fibrosis through regulating Tp53
Idiopathic pulmonary fibrosis (IPF) is a deadly respiratory condition distinguished by gradual fibrotic restructuring and diminishing pulmonary capacity, with cellular senescence serving as a critical factor in its pathogenesis. This study investigated the function of Sine oculis homeobox homologue 1 (Six1), a transcription factor, in pulmonary fibrosis (PF) and assessed its therapeutic potential as a target. The expression of Six1 was reduced in type II alveolar epithelial cells (AECII) in both patients with IPF and mouse models of PF induced by bleomycin (BLM). Conditional overexpression of Six1 in AECII exacerbated fibrosis severity, as confirmed by histological analysis and impaired lung function. RNA sequencing indicated the involvement of Six1 in pathways related to immune response, inflammation, and cellular senescence. Mechanistic studies revealed that Six1 promotes cellular senescence in AECII by directly upregulating Tp53 transcription, a process mitigated by treatment with PFN-α, a Tp53 inhibitor. Inhibition of Six1 using the specific repressor NCGC00378430 (NCG) attenuated fibrotic changes and improved pulmonary function in both Six1-overexpressing and wild-type mice. These findings suggest that Six1 is a contributor to the progression of IPF by regulating AECII senescence, emphasizing the therapeutic potential of targeting Six1 to alleviate PF. This study underscores the necessity of exploring Six1 inhibitors further as promising candidates for treating IPF.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.